TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03724279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ByCross Atherectomy and Thrombectomy
Description: After assessment of the lesion by angiography the ByCross is advanced over a 0.035 guidewire through a sheath to the occlusion. Activation will rotate the shaft and start aspiration. Under fluoroscopy the ByCross is advanced continuously over the wire. in case passage is not possible the ByCross tip is advanced into the occlusion for 10mm, then wire is advanced to check is passage is possible, this is repeated until passage by the wire is achieved. At harder lesion the speed is set to high. Once the occlusion is crossed the ByCross tip is enlarged, device is advanced once more to increase opening. Additional adjunctive treatment may be performed per physician's discretion and according to standard of care. Performance criteria of the intervention is to achieved more than 70% opening.
Study: NCT02315040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVIE
Description: EVIE is a small, mechanical, single use pump that mimics natural fertilization by introducing sperm into the uterus over a period of 4 hours, rather than all at once as in conventional IUI

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Intrauterine Insemination
Description: standard intrauterine insemination procedure
Study: NCT01393210

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low calorie diet plus beta-glucan
Description: beta-glucan 1.3D-1.6D, together with a low calorie diet, 500 mg once daily for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low-calorie diet
Description: low-calorie diet only for 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: low-calorie diet
Description: low-calorie diet only for 12 weeks.
Study: NCT00887159

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study: NCT00483678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: psychosocial assessment and care

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: psychosocial assessment and care
Study: NCT03344783

Intervention type: OTHER
Intervention: PUFA and R-TFA
Description: PUFA and R-TFA exposure were assessed mainly from maternal dietary, blood sample or breast milk. Exposure period was restricted to early life. Dietary PUFA and R-TFA were measured by food-frequency questionnaire (FFQ) or diet history questionnaire (DHQ). The profile of PUFA and R-TFA in the blood sample and breast milk were examined by using gas chromatography
Study: NCT02915627

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of Antishock garment
Description: anti-shock garments are applied. Participants will then be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of Antishock garment
Description: anti-shock garments are applied. Participants will then be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Application of Antishock garment
Description: anti-shock garments are applied. Participants will then be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
Study: NCT04068077

Intervention type: DEVICE
Intervention: ApolloVue™ S100 image system, Viper1-S003
Description: The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for experimental group.
Study: NCT03268408

Intervention type: BEHAVIORAL
Intervention: Baby Newsletter
Description: eight newsletters sent home to newborns' parents with advices and recommendations on child care and development
Study: NCT02479204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-334441 2 mg
Description: capsule containing ACT-334441 at a strength of 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-334441 2 mg
Description: capsule containing ACT-334441 at a strength of 2 mg
Study: NCT05235555

Intervention type: DEVICE
Intervention: Transcatheter heart valve (THV) with CE approval
Description: TAVI trough femoral access or alternative routes
Study: NCT02479204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-334441 4 mg
Description: capsule containing ACT-334441 at a strength of 4 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-334441 4 mg
Description: capsule containing ACT-334441 at a strength of 4 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: ACT-33441-matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: ACT-33441-matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: film-coated tablet containing atenolol at a strength of 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: film-coated tablet containing atenolol at a strength of 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem ER
Description: film-coated tablet containing diltiazem at a strength of of 120 mg
Study: NCT00045630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study: NCT02479204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem ER
Description: film-coated tablet containing diltiazem at a strength of of 120 mg
Study: NCT02334072

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal mask classical application
Description: Laryngeal mask classical application will be done following induction of anesthesia and anesthesia will be conducted by this device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-gel laryngeal mask application
Description: I-gel laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cobra laryngeal mask application
Description: Cobra laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supreme laryngeal mask application
Description: Supreme laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proseal laryngeal mask application
Description: Proseal laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
Study: NCT02554799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 formulation A
Description: MMV390048 formulation A, tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 formulation A
Description: MMV390048 formulation A, tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 formulation B
Description: MMV390048 formulation B, tablet
Study: NCT00045630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Study: NCT03471104

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PAID in clinical diabetes consultations
Description: The intervention starts when participants complete PROMs before an annual consultation. The physician reviews the PAID (problem areas in diabetes scale) scores with the participant. Participants with one or more single PAID item(s) scored 3 or 4, or a PAID score ≥30, will be referred to extra follow-up which will consist of at least two diabetes nurse consultations. The nurses will follow a communication manual based on key elements from empowerment theory and self-determination theory.~The participants then complete the PROMs prior to the next annual consultation with the physician.
Study: NCT04721938

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Systematic weight loss intervention
Description: Weight reduction through life style changes in diet and exercise by the following means:~* Counselling with a Nutritionist Nurse on diet and exercise~* Online Smartphone coaching program (Life-sum App)~* Motivational and adjustment dialogue and counselling with Nutritionist Nurse including anthropometric measures every month
Study: NCT02554799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV390048 formulation B
Description: MMV390048 formulation B, tablet
Study: NCT04047368

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rotablation
Description: Percutaneous Coronary Intervention using Rotablation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Lithoplasty
Description: Percutaneous Coronary Intervention using Lithoplasty
Study: NCT02786212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study: NCT01448889

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100% oxigen
Description: patients will recive 100% oxigen in a mask with reservoir from the begginind of the procedure to 4 hours after its termination

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients will recive 21% oxigen (room air) in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
Study: NCT03773666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a monoclonal antibody (an antibody is a protein produced by the body's immune system) that works by blocking the Programmed Cell Death Ligand 1 (PD-L1), a protein on cancer cells that stops the body's immune system from killing cancer cells.
Study: NCT03300219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to Occupational Performance
Description: CO-OP is a top-down, task-oriented, client-centered approach that uses an iterative process of dynamic performance analysis and guided discovery to enable individuals to identify strategies that will improve performance
Study: NCT03773666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab is a monoclonal antibody (an antibody is a protein produced by the body's immune system) that works by blocking the Programmed Cell Death Ligand 1 (PD-L1), a protein on cancer cells that stops the body's immune system from killing cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleclumab
Description: Oleclumab is a monoclonal antibody that works by reducing the amount of adenosine, a small molecule called a metabolite that binds to adenosine receptors on immune cells to regulate the immune system and suppress the immune response. Reducing the amount of immunosuppressive adenosine can increase the body's immune response to kill cancer cells.
Study: NCT04172350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iCareBreast
Description: The iCareBreast BuddyCare mobile app is an interactive surgery preparation and recovery app for patients. It is a patient-centric care coordination and patient engagement mobile app that supports patients' perioperative journey. The app provides day-to-day information throughout the perioperative journey to patients from 2 weeks before surgery to 2 weeks after the surgery. Meanwhile the healthcare professional can monitor patients' use of the app. That is, the iCareBreast App provides patients with all the information about the surgery-related procedure and treatment via an efficient, user-friendly and interactive timeline. Patients will receive pop-up reminders daily for them to use the app. The objective of this app is to allow each patient to focus on caring for herself as a patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Routine care provided by the hospital includes general information regarding pre-operation preparation and post-operative care (e.g. wound care, pain management and physiotherapy).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care
Description: Routine care provided by the hospital includes general information regarding pre-operation preparation and post-operative care (e.g. wound care, pain management and physiotherapy).
Study: NCT03183063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4DCT and SPECT/CT
Description: Each patient will receive two 4DCT followed by SPECT/CT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4DCT with BiPAP and SPECT/CT
Description: Each patient will receive two 4DCT, with the second scan obtained with positive pressure breathing via BiPAP, followed by SPECT/CT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4DCT with CTA in suspected PE
Description: Each patient will receive 4DCT before or after CTA for suspected PE
Study: NCT01805687

Intervention type: DRUG
Group type: OTHER
Intervention: Zileuton extended release
Study: NCT02330354

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Healthy Me, Healthy We
Description: The intervention - Healthy Me, Healthy We - is a 7-month social marketing campaign designed to improve preschool children's (3-4 years) diet and physical activity behaviors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Me, Healthy We
Description: The intervention - Healthy Me, Healthy We - is a 7-month social marketing campaign designed to improve preschool children's (3-4 years) diet and physical activity behaviors.
Study: NCT03765216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2L Polyethylene Glycol (PEG)
Description: Participants in Group A and Low risk patients in group B are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2L Polyethylene Glycol (PEG)
Description: Participants in Group A and Low risk patients in group B are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4L Polyethylene Glycol (PEG)
Description: High risk patients in Group B will receive 4 L Polyethylene Glycol (PEG) regimen
Study: NCT00078806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Administered by subcutaneous injection twice a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Administered by subcutaneous injection twice a week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Administered by subcutaneous injection twice a week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection twice a week
Study: NCT03190135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BOKS: 2 day a week before-school physical activity program
Description: Students participate in BOKS, a before-school physical activity program for 12 weeks, 2 times per week.
Study: NCT03561519

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplantation (FMT)
Description: Fecal suspension administered in colonoscopy into the cecum of the patient.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: As a placebo a fecal suspension made of patients own feces is administered into the cecum of the patient in colonoscopy.
Study: NCT02567656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP6530
Description: Tablet starting at 200 mg
Study: NCT00920738

Intervention type: OTHER
Intervention: metabolic assessment
Description: Physical examination, medical history, blood pressure, anthropometrics, laboratory studies and other procedures (body composition, bone density, growth hormone, vascular, functional mobility, body fat assessments, etc).
Study: NCT03190135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BOKS: 3 day a week before-school physical activity program
Description: Students participate in BOKS, a before-school physical activity program for 12 weeks, 3 times per week.
Study: NCT03394742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer support
Description: Peer support persons are breast cancer survivors, who were educated to give peer support. They contacted participants by telephone.
Study: NCT03870464

Intervention type: DIAGNOSTIC_TEST
Intervention: CT-scans extended
Description: CT scans of thorax, abdomen and lower extremities are performed - screening for venous trombolisms at baseline and at 6 months in each patient. If VTE is diagnosed, medications according to guidelines will be administered.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI scan of the brain
Description: MRI scan of the brain screening for brain metastases. If brain metastases are diagnosed - the possibility of giving radiotherapy along the course of ICI is discussed with the patient. In case of brain metastases consecutive MRI scans of the brain will be performed in order to follow the course (natural or post-radiotherapy) of the disease.

Intervention type: OTHER
Intervention: Prospective registration of irAEs
Description: irAEs are registered according to Common Terminology Criteria for Adverse Events version 4.0 by a medical doctor or trained experienced clinical nurse.

Intervention type: BEHAVIORAL
Intervention: Quality of Life questionnaires
Description: Participants fill out two Quality of Life questionnaires. The European Organization of Research and Treatment of Cancer, Quality of Life -30 questionnaire (EORTC QoL-30) and the European Questionnaire - 5 dimensions-5-level questionnaire (Euro EQ-5D-5L).
Study: NCT00286624

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Islets of Langerhans
Description: Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. First infusion to contain at least 5,000 islet equivalents/kg body weight. Subsequent infusions to contain at least 3,000 islet equivalents/kg body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Loading dose of 3 mg PO on day -2 relative to transplant, followed at least 12 hours later by dose of 1.5 mg PO BID. The daily dose will be adjusted according to the whole blood 12-hr trough to target 3-15 ng/ml for the first 3 months and 3-12 ng/ml thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: A total of 6 mg/kg IV over 12 hours on days -2, -1, 0, +1, and +2. The dose will be 0.5 mg/kg on day -2, 1.0 mg/kg on day -1, and 1.5 mg/kg on days 0, +1, and +2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine started on day +1 relative to the first islet transplant. Initial dose of 3 mg/kg/day administered in 2 divided doses; then adjusted to maintain target levels of 400 (350-500) ng/mL for the first three months following islet transplant and 300 (200-350) ng/mL thereafter.
Study: NCT01947335

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IVUS-guided PCI
Description: Intravascular ultrasound guided percutaneous coronary intervention
Study: NCT01798147

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DEB TACE
Description: DEB TACE every 6 weeks until either no viable tumor or endpoint reached.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SIRT
Description: Selective Internal Radiotherapy once at the beginning of the study. Follow up until endpoint.
Study: NCT00852579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Daily dose 250mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00728156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: 75 milligrams, oral, clopidogrel, one tablet daily, for seven days after the baseline chamber study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo: Hydroxy methyl cellulose, similar in weight to the active medication 75 mgs, oral tablets, once a day
Study: NCT01444001

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine
Description: 0.5 mL, intramuscular
Study: NCT00920738

Intervention type: OTHER
Intervention: metabolic assessment
Description: Physical examination, medical history, blood pressure, anthropometrics, laboratory studies and other procedures (body composition, bone density, growth hormone, vascular, functional mobility, body fat assessments, etc).

Intervention type: OTHER
Intervention: questionnaire administration
Description: Dietary habits will be evaluated using the Youth/ Adolescent Questionnaire (YAQ)and the Modifiable Activity Questionnaire for Adolescents (MAQA) will be used to assess participation in leisure time and competitive activities during the past year will be administered on Day 2.

Intervention type: OTHER
Intervention: questionnaire administration
Description: Dietary habits will be evaluated using the Youth/ Adolescent Questionnaire (YAQ)and the Modifiable Activity Questionnaire for Adolescents (MAQA) will be used to assess participation in leisure time and competitive activities during the past year will be administered on Day 2.
Study: NCT03549468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low level tragus stimulation
Description: All patients will undergo sequentially: sham stimulation; LLTS (5Hz), LLTS (20Hz). The sequence will be repeated during atrial pacing at 100bpm
Study: NCT04009460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES101
Description: ES101 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES101
Description: ES101 is administered via intravenous infusion, once every 14 days, every 28 days as a treatment cycle.